|Bid||58.68 x 3100|
|Ask||58.69 x 2900|
|Day's Range||58.55 - 59.74|
|52 Week Range||46.48 - 64.94|
|Beta (5Y Monthly)||0.21|
|PE Ratio (TTM)||38.71|
|Forward Dividend & Yield||1.40 (2.38%)|
|Ex-Dividend Date||Feb 25, 2021|
|1y Target Est||63.60|
The Institute for Antiracism in Medicine Co-Founder & The University of Illinois College of Medicine Assistant Professor of Clinical & Family Medicine Dr. Brittani James joins Yahoo Finance Live to discuss the latest updates amid the COVID-19 pandemic.
The PRAC of the European Medicines Agency (EMA) has advised against giving AstraZeneca's (AZN) Vaxzevria COVID-19 vaccine to people with a history of capillary leak syndrome, a rare blood disorder.
AstraZeneca stock has yo-yoed as challenges mount for its coronavirus vaccine. But the company's 2021 guidance, raised in April, doesn't count on the Covid vaccine. Is AZN stock a buy?